A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Incidence of first biopsy- proven acute rejection (Banff Grade≥ 1) (BCAR rate) and infections
研究概览
简要总结
The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
详细描述
This is a single center, investigator initiated, pilot study to assess the safety and efficacy of Alefacept in combination with Alemtuzumab induction and Myfortic with rapid steroid and calcineurin inhibitor withdrawal in de novo Kidney transplant recipients. Induction therapy involves single dose Alemtuzumab and steroids peri-operatively. Tacrolimus will be administered for the first 30 days post-transplantation. Alefacept will be administered IV for the first two doses followed by subcutaneous injections weekly until 12 weeks post-transplant followed by monthly injections for the rest of the duration of the study. The primary outcomes are safety and efficacy outcomes, including biopsy proven acute rejection episodes, infectious complications or other serious adverse events. Secondary outcomes include T-helper differentiation, cytokine production and T regulatory cell generation assessed by immune monitoring assays.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Institutional Review Board (IRB) approved written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization for U.S. sites, or equivalent privacy language as per national regulations, obtained from the subject or legally authorized representative prior to study-related procedures (including withdrawal of prohibited medication, if applicable)
- •Recipient of a kidney from a non-HLA identical related living donor, a non- related living donor, or deceased donor
- •Recipient of a de novo kidney transplant
- •≥ 18 years of age
- •Anticipated to receive first oral dose of tacrolimus within 48 hours of transplant procedure
- •Female subjects of child bearing potential must have a negative urine or serum pregnancy test, and must agree to maintain effective birth control during the study
- •Healthy donor is eligible for the blood draw if:
- •Institutional Review Board (IRB) approved written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization for U.S. sites, or equivalent privacy language as per national regulations, is obtained from subject prior to any study-related procedures
- •Subject is a donor to a de novo kidney transplant subject who is enrolled in the study or a self declared healthy volunteer who is not a kidney donor for a subject enrolled in the study
- •≥ 18 years of age
排除标准
- •Previously received or is receiving an organ transplant other than a kidney
- •Sensitivity to iodine
- •Will receive a transplant from a non-heart beating donor (donation after cardiac death - DCD)
- •Receives a transplant from an HLA identical related living donor
- •Will receive a solitary kidney from a deceased donor < 5 years of age
- •Will receive a kidney with an anticipated cold ischemia time (CIT) of > 30 hours
- •Will receive an ABO incompatible donor kidney
- •Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
- •Recipient has a positive T or B cell crossmatch by investigational site's standard method of determination. For recipients where a flow cytometry crossmatch is performed and is positive in either T or B cell testing, recipients are excluded only if donor specific, anti-HLA antibody is detected by flow cytometry based, specific anti-HLA antibody testing.
- •Current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
- •Significant liver disease
- •Serologically negative for cytomegalovirus (CMV) with serologically positive CMV donor
- •Serologically negative for Epstein Barr virus
- •Has received intravenous immunoglobulin (IVIG) therapy in the three months prior to first dose of study drug
- •Uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives
- •Concurrently participating in another drug study or has received an investigational drug within 28 days prior to transplant
- •Known hypersensitivity to alefacept, alemtuzumab, tacrolimus, mycophenolic acid, corticosteroids, or any of their components
- •Any form of substance abuse, psychiatric disorder, or a condition that in the opinion of the Investigator could invalidate communication with the Investigator
- •Subject is pregnant or lactating
- •Subject is unlikely to comply with the visits scheduled in the protocol
- •Subject will receive a kidney transplant from an expanded criteria donor (ECD)
- •Will receive a kidney transplant from a CDC high risk donor
- •Healthy donor subject will be excluded from participation if any of the following apply:
- •Unable to comprehend the investigational nature of the protocol participation
- •Complete blood count results determined to be outside the normal ranges
研究组 & 干预措施
Alefacept (ASP0485)
Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
干预措施: Alefacept (ASP0485) (Drug)
结局指标
主要结局
Incidence of first biopsy- proven acute rejection (Banff Grade≥ 1) (BCAR rate) and infections
时间窗: At 12 months post-transplant
To assess the safety and efficacy of alefacept in combination with a single dose of alemtuzamab induction and Enteric coated Mycophenolic sodium with calcineurin inhibitor withdrawal and rapid elimination of corticosteroids by examining the incidence of first biopsy-proven acute rejection (Banff Grade≥ 1) (BCAR rate) and the incidence and clinical presentation of infections.
次要结局
- Affect on Immune cells(Up to 12 months post-transplant)
- Assess secondary outcome measures of efficacy and safety(Upto 12 months post-transplant)
研究者
M. Javeed Ansari
Assistant Professor of Medicine
Northwestern University